# OnCo record nct06419179 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06419179/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06419179", "NCT06419179" ;
  schema:name "Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens"@en ;
  schema:alternateName "GUIDANCE"@en ;
  schema:description "A phase 2 trial of durvalumab and olaparib in lung cancer, run by University of Cologne, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06419179/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06419179> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/olaparib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .